Future Outlook: The acquisition of the Manager is expected to reduce costs, enhance economic returns, increase shareholder alignment, enhance corporate governance, ensure management continuity, and simplify the corporate structure. The transaction is anticipated to close in the second quarter of 2025. Operational Strategy: Royalty Pharma continues to be a leading funder of innovation in the biopharmaceutical industry, both directly and indirectly, by partnering with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and by acquiring existing royalties from original innovators. SEC Filing: Royalty Pharma plc [ RPRX ] - 10-Q - May. 08, 2025